Drug Trial Radar · NCT05352178
Metastasis-directed Therapy for Oligorecurrent Prostate Cancer
Last checked: Nov 19, 2026Latest source record: Jul 3, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
873
Planned (sponsor's estimate)
Start
Apr 20, 2022
Primary completion
Apr 25, 2027
Study completion Apr 25, 2032
Sponsor
- Lead sponsor
- Universitaire Ziekenhuizen KU LeuvenAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Apr 28, 2022
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- Male only, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The aim is to investigate whether the addition of short-term androgen deprivation therapy (ADT) during 1 month or short-term ADT during 6 months together with an androgen receptor targeted therapy (ARTA) to metastasis-directed therapy (MDT) significantly prolongs poly-metastatic free survival (PMFS) and/or metastatic castration-refractory prostate cancer free survival (mCRPC-FS) in patients with oligorecurrent hormone sensitive prostate cancer.
Conditions
- Prostate Cancer
- Prostate Cancer Recurrent
- Prostate Cancer Metastatic
- Metastatic Cancer
- Oligometastatic Disease
- Oligometastasis
- Hormone Sensitive Prostate Cancer
Interventions
Radiotherapy (SBRT) and/or surgery (metastasectomy)Other
Metastasis-directed therapay (surgery and/or radiotherapy) as treatment for oligorecurrent lesions
Androgen deprivation therapyDrug
Arm B: gosereline 3.6 mg sc, leuproreline 7.5 mg sc, triptoreline 3.75 mg im Arm C: gosereline 3.6 mg sc 1x/month or gosereline 10.8 mg sc or leuproreline 7.5 mg sc 1x/month or leuproreline 45 mg sc or triptoreline 3.75 mg im 1x/month or triptoreline 11.5 mg im 1x/3months or triptoreline 22.5 mg im
Androgen receptor targeted therapyDrug
Enzalutamide
Primary outcomes
What the sponsor says the trial is designed to measure.
- Poly-metastatic free survival (PMFS)Time frame: up to 5 years after MDT
Locations
1 site in 1 country. Site status is shown where the registry gives one.
University Hospitals Leuven
Leuven, Belgium · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.